506 related articles for article (PubMed ID: 27349355)
61. Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma.
Hayasaka K; Shiono S; Matsumura Y; Yanagawa N; Suzuki H; Abe J; Sagawa M; Sakurada A; Katahira M; Takahashi S; Endoh M; Okada Y
Ann Thorac Surg; 2018 Jun; 105(6):1648-1654. PubMed ID: 29486179
[TBL] [Abstract][Full Text] [Related]
62. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
[TBL] [Abstract][Full Text] [Related]
63. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
[TBL] [Abstract][Full Text] [Related]
64. Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.
Zou J; Lv T; Zhu S; Lu Z; Shen Q; Xia L; Wu J; Song Y; Liu H
Thorac Cancer; 2017 May; 8(3):260-270. PubMed ID: 28383802
[TBL] [Abstract][Full Text] [Related]
65. Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.
Lee YJ; Park IK; Park MS; Choi HJ; Cho BC; Chung KY; Kim SK; Chang J; Moon JW; Kim H; Choi SH; Kim JH
J Cancer Res Clin Oncol; 2009 Dec; 135(12):1647-54. PubMed ID: 19517135
[TBL] [Abstract][Full Text] [Related]
66. Detection of an EGFR mutation in cytological specimens of lung adenocarcinoma.
Mohar B; Smojver Ježek S; Rajković Molek K; Štemberger C; Kurpis M; Kupanovac Ž; Samaržija M; Jonjić N; Grahovac B
Cytopathology; 2016 Dec; 27(6):444-451. PubMed ID: 26990359
[TBL] [Abstract][Full Text] [Related]
67. Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
Yotsukura M; Yasuda H; Shigenobu T; Kaseda K; Masai K; Hayashi Y; Hishida T; Ohtsuka T; Naoki K; Soejima K; Betsuyaku T; Asamura H
Lung Cancer; 2017 Jul; 109():45-51. PubMed ID: 28577949
[TBL] [Abstract][Full Text] [Related]
68. Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation.
Erdogan B; Kodaz H; Karabulut S; Cinkaya A; Tozkir H; Tanriverdi O; Cabuk D; Hacioglu MB; Turkmen E; Hacibekiroglu I; Uzunoglu S; Cicin I
Bosn J Basic Med Sci; 2016 Nov; 16(4):280-285. PubMed ID: 27371767
[TBL] [Abstract][Full Text] [Related]
69. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
[TBL] [Abstract][Full Text] [Related]
70. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Jain A; Lim C; Gan EM; Ng DZ; Ng QS; Ang MK; Takano A; Chan KS; Tan WM; Kanesvaran R; Toh CK; Loo CM; Hsu AA; Devanand A; Lim CH; Koong HN; Koh T; Fong KW; Yap SP; Kim SW; Chowbay B; Oon L; Lim KH; Lim WT; Tan EH; Tan DS
PLoS One; 2015; 10(5):e0123587. PubMed ID: 25955322
[TBL] [Abstract][Full Text] [Related]
71. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
72. Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?
Zhang Y; Ma Y; Li Y; Shen X; Yu Y; Pan Y; Zhang Y; Yu S; Zheng D; Zhao Y; Hu H; Sun Y; Zhang Y; Xiang J; Chen H
J Cancer Res Clin Oncol; 2018 Jan; 144(1):165-171. PubMed ID: 29026990
[TBL] [Abstract][Full Text] [Related]
73. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras.
Takamochi K; Oh S; Matsuoka J; Suzuki K
Lung Cancer; 2012 Mar; 75(3):313-20. PubMed ID: 22209037
[TBL] [Abstract][Full Text] [Related]
74. Frequency of epidermal growth factor receptor mutations in Jordanian lung adenocarcinoma patients at diagnosis.
Obeidat N; Awidi A; Ababneh N; Shomaf M; Al-Adaily T; Jaber M; Al-Khateeb M; Abbasi S
J Cancer Res Ther; 2016; 12(2):616-9. PubMed ID: 27461620
[TBL] [Abstract][Full Text] [Related]
75. Prognostic outcomes and recurrence patterns in resected stage I lung adenocarcinoma harbouring atypical epidermal growth factor receptor mutations.
Chen T; Wen J; Li Y; Deng J; Zhong Y; Hou L; She Y; Xie D; Chen C
Eur J Cardiothorac Surg; 2024 Jan; 65(1):. PubMed ID: 38001033
[TBL] [Abstract][Full Text] [Related]
76. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
77. [Relationship of epidermal growth factor receptor gene mutations, clinicopathologic features and prognosis in patients with non-small cell lung cancer].
Fan MJ; Li HG; Lü ZQ; Zhang HZ; Shen XM
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):679-82. PubMed ID: 22321547
[TBL] [Abstract][Full Text] [Related]
78. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
Lee JS; Kim HR; Lee CY; Shin M; Shim HS
Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
[TBL] [Abstract][Full Text] [Related]
79. Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma.
Guo Z; Yi F; Yin W; Zhang Y; Li Q; Gu Y; Xiao Y; Cao B; Ma L; Liang L
Thorac Cancer; 2017 May; 8(3):159-169. PubMed ID: 28220630
[TBL] [Abstract][Full Text] [Related]
80. Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer.
Iwakiri S; Mino N; Takahashi T; Sonobe M; Nagai S; Okubo K; Wada H; Date H; Miyahara R
Cancer; 2009 Jun; 115(11):2580-93. PubMed ID: 19309748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
